-
Je něco špatně v tomto záznamu ?
IL-2, IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple sclerosis
M. Petržalka, E. Meluzínová, J. Libertínová, H. Mojžišová, J. Hanzalová, P. Ročková, M. Elišák, S. Kmetonyová, J. Šanda, O. Sobek, P. Marusič
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Directory of Open Access Journals
od 2006
Free Medical Journals
od 2006
Public Library of Science (PLoS)
od 2006
PubMed Central
od 2006
Europe PubMed Central
od 2006
ProQuest Central
od 2006-12-01
Open Access Digital Library
od 2006-10-01
Open Access Digital Library
od 2006-01-01
Open Access Digital Library
od 2006-01-01
Medline Complete (EBSCOhost)
od 2008-01-01
Nursing & Allied Health Database (ProQuest)
od 2006-12-01
Health & Medicine (ProQuest)
od 2006-12-01
Public Health Database (ProQuest)
od 2006-12-01
ROAD: Directory of Open Access Scholarly Resources
od 2006
- MeSH
- biologické markery mozkomíšní mok MeSH
- chitinasy metabolismus MeSH
- chronická nemoc MeSH
- interleukin-2 metabolismus MeSH
- interleukin-6 metabolismus MeSH
- lidé MeSH
- recidiva MeSH
- roztroušená skleróza * mozkomíšní mok diagnóza farmakoterapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: The possibility to better predict the severity of the disease in a patient newly diagnosed with multiple sclerosis would allow the treatment strategy to be personalized and lead to better clinical outcomes. Prognostic biomarkers are highly needed. OBJECTIVE: To assess the prognostic value of intrathecal IgM synthesis, cerebrospinal fluid and serum IL-2, IL-6, IL-10, chitinase 3-like 2 and neurofilament heavy chains obtained early after the onset of the disease. METHODS: 58 patients after the first manifestation of multiple sclerosis were included. After the initial diagnostic assessment including serum and cerebrospinal fluid biomarkers, all patients initiated therapy with either glatiramer acetate, teriflunomide, or interferon beta. To assess the evolution of the disease, we followed the patients clinically and with MRI for two years. RESULTS: The IL-2:IL-6 ratio (both in cerebrospinal fluid) <0.48 (p = 0.0028), IL-2 in cerebrospinal fluid ≥1.23pg/ml (p = 0.026), and chitinase 3-like 2 in cerebrospinal fluid ≥7900pg/ml (p = 0.033), as well as baseline EDSS ≥1.5 (p = 0.0481) and age <22 (p = 0.0312), proved to be independent markers associated with shorter relapse free intervals. CONCLUSION: The IL-2:IL-6 ratio, IL-2, and chitinase 3-like 2 (all in cerebrospinal fluid) might be of value as prognostic biomarkers in early phases of multiple sclerosis.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22017943
- 003
- CZ-PrNML
- 005
- 20220804134456.0
- 007
- ta
- 008
- 220720s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0270607 $2 doi
- 035 __
- $a (PubMed)35759479
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Petržalka, Marko $u Second Faculty of Medicine, Department of Neurology, Charles University and Motol University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000309122656
- 245 10
- $a IL-2, IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple sclerosis / $c M. Petržalka, E. Meluzínová, J. Libertínová, H. Mojžišová, J. Hanzalová, P. Ročková, M. Elišák, S. Kmetonyová, J. Šanda, O. Sobek, P. Marusič
- 520 9_
- $a BACKGROUND: The possibility to better predict the severity of the disease in a patient newly diagnosed with multiple sclerosis would allow the treatment strategy to be personalized and lead to better clinical outcomes. Prognostic biomarkers are highly needed. OBJECTIVE: To assess the prognostic value of intrathecal IgM synthesis, cerebrospinal fluid and serum IL-2, IL-6, IL-10, chitinase 3-like 2 and neurofilament heavy chains obtained early after the onset of the disease. METHODS: 58 patients after the first manifestation of multiple sclerosis were included. After the initial diagnostic assessment including serum and cerebrospinal fluid biomarkers, all patients initiated therapy with either glatiramer acetate, teriflunomide, or interferon beta. To assess the evolution of the disease, we followed the patients clinically and with MRI for two years. RESULTS: The IL-2:IL-6 ratio (both in cerebrospinal fluid) <0.48 (p = 0.0028), IL-2 in cerebrospinal fluid ≥1.23pg/ml (p = 0.026), and chitinase 3-like 2 in cerebrospinal fluid ≥7900pg/ml (p = 0.033), as well as baseline EDSS ≥1.5 (p = 0.0481) and age <22 (p = 0.0312), proved to be independent markers associated with shorter relapse free intervals. CONCLUSION: The IL-2:IL-6 ratio, IL-2, and chitinase 3-like 2 (all in cerebrospinal fluid) might be of value as prognostic biomarkers in early phases of multiple sclerosis.
- 650 _2
- $a biologické markery $x mozkomíšní mok $7 D015415
- 650 _2
- $a chitinasy $x metabolismus $7 D002688
- 650 _2
- $a chronická nemoc $7 D002908
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a interleukin-2 $x metabolismus $7 D007376
- 650 _2
- $a interleukin-6 $x metabolismus $7 D015850
- 650 12
- $a roztroušená skleróza $x mozkomíšní mok $x diagnóza $x farmakoterapie $7 D009103
- 650 _2
- $a recidiva $7 D012008
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Meluzínová, Eva $u Second Faculty of Medicine, Department of Neurology, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Libertínová, Jana $u Second Faculty of Medicine, Department of Neurology, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Mojžišová, Hana $u Second Faculty of Medicine, Department of Neurology, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Hanzalová, Jitka $u Second Faculty of Medicine, Department of Neurology, Charles University and Motol University Hospital, Prague, Czech Republic $u Second Faculty of Medicine, Department of Immunology, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Ročková, Petra $u Second Faculty of Medicine, Department of Neurology, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Elišák, Martin $u Second Faculty of Medicine, Department of Neurology, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Kmetonyová, Silvia $u Second Faculty of Medicine, Department of Neurology, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Šanda, Jan $u Second Faculty of Medicine, Department of Radiology, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Sobek, Ondřej $u Topelex sro, Laboratory for CSF, Neuroimmunology, Pathology and Special Diagnostics, Prague, Czech Republic
- 700 1_
- $a Marusič, Petr $u Second Faculty of Medicine, Department of Neurology, Charles University and Motol University Hospital, Prague, Czech Republic
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 17, č. 6 (2022), s. e0270607
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35759479 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804134450 $b ABA008
- 999 __
- $a ok $b bmc $g 1821845 $s 1169186
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 17 $c 6 $d e0270607 $e 20220627 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
- LZP __
- $a Pubmed-20220720
